Workflow
Heart Failure with Reduced Ejection Fraction (HFrEF)
icon
Search documents
Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction
Newsfilterยท 2025-03-11 13:09
Company Overview - Medera Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for difficult-to-treat and currently incurable diseases [8] - The company operates through two business units: Novoheart and Sardocor, which are involved in preclinical and clinical development respectively [8][10] Clinical Trial Update - Medera has completed patient dosing in its MUSIC-HFrEF Phase 1/2a clinical trial for the gene therapy candidate SRD-001, targeting heart failure with reduced ejection fraction (HFrEF) [1][4] - The trial is an open-label, uncontrolled study with two cohorts: Cohort A (low-dose, 6 patients) and Cohort B (high-dose, 3 patients) [3] - Preliminary data presented at the 7th Annual Meeting of the American Society of Gene and Cell Therapy indicated an acceptable safety profile and clinically meaningful improvements in heart function metrics at six and twelve months post-infusion [3][4] Disease Context - HFrEF is a prevalent form of heart disease, accounting for half of the estimated 64.3 million heart failure cases globally, and is currently considered an incurable disease [2][7] - The condition is characterized by progressive and irreversible impairment of cardiac function, leading to debilitating symptoms and high mortality rates, highlighting the urgent need for disease-modifying therapies like SRD-001 [7] Future Prospects - The completion of enrollment in the Phase 1/2a trial is seen as a crucial milestone for the development of cardiac gene therapy for patients with advanced heart failure [4] - Medera's CEO expressed optimism regarding the results, indicating that optimized dosages are making a difference in patient outcomes [5] Additional Information - SRD-001 is an investigational gene therapy using an adeno-associated virus vector to express the SERCA2a transgene in patients with HFrEF [6] - Sardocor, a unit of Medera, is focused on the clinical development of novel therapies and has received FDA IND clearances for multiple ongoing clinical trials targeting various forms of heart failure and related conditions [11]